Home › Funds › MOODY LYNN LIEBERSON & WALKER, LLC › VRTX

MOODY LYNN LIEBERSON & WALKER, LLC position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

MOODY LYNN LIEBERSON & WALKER, LLC reported holding 56,875 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$29.7M, representing 1.56% of its reported portfolio and ranking #18 among its reported holdings. MOODY LYNN LIEBERSON & WALKER, LLC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)56.88K sh
Reported value held$29.73M
Portfolio Weight1.56%
First reportedQ3 2023
Last changeHold
Updated2026-10-14

Last updated: 2026-10-14 · Source: SEC EDGAR Form 13F-HR

How MOODY LYNN LIEBERSON & WALKER, LLC's VRTX position evolved

MOODY LYNN LIEBERSON & WALKER, LLC first disclosed a stake in VRTX in Q3 2023 at 69,601 shares (US$24.2M). The position peaked in Q3 2024 at 65,207 shares, worth US$30.3M. Across 13 filings, MOODY LYNN LIEBERSON & WALKER, LLC increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 56,875 shares valued at US$29.7M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 69.60K $24.20M New
Q4 2023 59.51K $24.21M Reduce
Q1 2024 61.97K $25.90M Add
Q2 2024 56.42K $26.45M Reduce
Q3 2024 65.21K $30.33M Add
Q4 2024 57.22K $23.04M Reduce
Q1 2025 57.26K $27.76M Hold
Q2 2025 58.08K $25.86M Add
Q3 2025 56.56K $22.15M Reduce
Q4 2025 54.99K $24.93M Reduce
Q1 2026 57.64K $25.74M Add
Q2 2026 56.62K $28.13M Reduce
Q3 2026 56.88K $29.73M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has MOODY LYNN LIEBERSON & WALKER, LLC held VRTX?

MOODY LYNN LIEBERSON & WALKER, LLC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is MOODY LYNN LIEBERSON & WALKER, LLC's current position in VRTX?

As of Q3 2026, MOODY LYNN LIEBERSON & WALKER, LLC holds 56.88K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $29.73M, representing 1.56% of its reported portfolio and ranking #18.

Has MOODY LYNN LIEBERSON & WALKER, LLC been buying or selling VRTX?

In the latest 13F filing (Q3 2026), MOODY LYNN LIEBERSON & WALKER, LLC held unchanged its position in VRTX. The position peaked in Q3 2024 at 65.21K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.